Resection for second and third primary lung cancer
โ Scribed by L. Penfield Faber
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 576 KB
- Volume
- 9
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
โฆ Synopsis
The continued increasing incidence of bronchogenic carcinoma increases the likelihood that a patient may develop a second or third primary tumor. We have carried out a second thoractomy for 114 patients who met our criteria of having a new primary lung cancer. These criteria were a different histologic cell type, a tumor-free interval of 24 mo, the second primary in the contralateral lung, or the new tumor in a separate and distinct ipsilateral lobe if the tumor was on the same side. There were 18 patients who had a thoracotomy for a third primary lung cancer and they met the same criteria. There were 73 segmental resections in the 132 thoracotomies, and a conservative resection is important to minimize postoperative complications. Operative mortality for the second resection group of patients was 8.8% (lo/ 114). There was one operative death in the 18 patients undergoing a third resection. The cumulative survival rate following a second resection in I14 patients with metachronous tumors was 33% at 5 yr and 20% at 10 yr. Early detection of a second and third primary lung cancer and surgical resection offers the greatest chance for long-term survival in this group of patients.
๐ SIMILAR VOLUMES
An unusually high association of other primary cancers (9.7%) was found during the analysis of 403 consecutive cases of carcinoma of the lung diagnosed at DGMC between 1960 and 1975. Incidence by stage included 17.3% for Stage I (75 cases) and 16.9% for Stage II (59 cases). Median survival by stage
There are only limited population-based data available regarding the risk of developing a second cancer after a diagnosis of lung carcinoma. ## METHODS. Data collected from the Cancer Registry of the Swiss Canton of Vaud (comprised of approximately 600,000 inhabitants) were used to estimate the i
One hundred seventy-one patients were studied in order to evaluate the clinical efficacy of the transfer factor (TF) for primary resected lung cancers under a randomized controlled trial. Eligible cases for evaluation were randomly chosen at 75 and 74 patients in TF and control groups, respectively.
## Abstract ## Background. Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for developing both pulmonary metastasis and second primary lung cancer (SPLC). The objective of this study was to determine survival characteristics of patients with pulmonary lesions after curative